Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678206 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
A Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
NCT04678206 is a Phase 2 study that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 310 participants.
The verdict
NCT04678206, a Phase 2 study, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Interventions
- DRUG Placebo
- DRUG BLU-5937
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04678206
The ClinicalTrials.gov registry entry for NCT04678206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04678206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04678206 about?
NCT04678206 is a clinical study titled "Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough". This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
What is the current status of trial NCT04678206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2020-12-07. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT04678206?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT04678206?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.